Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Author:

Herbst Roy S.1ORCID,Hatsukami Dorothy2ORCID,Acton Dana3ORCID,Giuliani Meredith4ORCID,Moushey Allyn5ORCID,Phillips Jonathan5ORCID,Sherwood Shimere5ORCID,Toll Benjamin A.6ORCID,Viswanath Kasisomayajula7ORCID,Warren Nicholas J.H.3ORCID,Warren Graham W.6ORCID,Alberg Anthony J.8ORCID

Affiliation:

1. 1Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.

2. 2Masonic Cancer Center, Minneapolis, Minnesota.

3. 3American Association for Cancer Research, Washington, D.C.

4. 4Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

5. 5American Society of Clinical Oncology, Alexandria, Virginia.

6. 6Medical University of South Carolina, Charleston, South Carolina.

7. 7Dana-Farber Cancer Institute, Boston, Massachusetts.

8. 8Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.

Abstract

Abstract Combustible tobacco use has reached historic lows, demonstrating the importance of proven strategies to reduce smoking since publication of the 1964 Surgeon General's report. In contrast, the use of electronic nicotine delivery systems (ENDS), specifically e-cigarettes, has grown to alarming rates and threatens to hinder progress against tobacco use. A major concern is ENDS use by youth and adults who never previously used tobacco. While ENDS emit fewer carcinogens than combustible tobacco, preliminary evidence links ENDS use to DNA damage and inflammation, key steps in cancer development. Furthermore, high levels of nicotine can also increase addiction, raise blood pressure, interfere with brain development, and suppress the immune system. The magnitude of long-term health risks will remain unknown until longitudinal studies are completed. ENDS have been billed as a promising tool for combustible tobacco cessation, but further evidence is needed to assess their potential efficacy for adults who smoke. Of concern, epidemiological studies estimate that approximately 15% to 42% of adults who use ENDS have never used another tobacco product, and another 36% to 54% “dual use” both ENDS and combustible tobacco. This policy statement details advances in science related to ENDS and calls for urgent action to end predatory practices of the tobacco industry and protect public health. Importantly, we call for an immediate ban on all non-tobacco-flavored ENDS products that contain natural or synthetic nicotine to reduce ENDS use by youth and adults who never previously used tobacco. Concurrently, evidence-based treatments to promote smoking cessation and prevent smoking relapse to reduce cancer incidence and improve public health remain top priorities for our organizations. We also recognize there is an urgent need for research to understand the relationship between ENDS and tobacco-related disparities.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3